Amylyx Pharmaceuticals Inc
AMLX
ISIN null / Valor 115580129
Amylyx Pharmaceuticals Inc
UMushroom community rating:
About company
Amylyx Pharmaceuticals is a publicly traded biotechnology company (Nasdaq: AMLX) that develops therapies for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and related central nervous system disorders. Its lead product, AMX0035 — marketed in the U.S. as Relyvrio — is an oral fixed‑dose combination of sodium phenylbutyrate and taurursodiol that completed late‑stage clinical testing for ALS and received U.S. regulatory approval; the company is commercializing that therapy while conducting additional clinical studies and pursuing regulatory filings in other jurisdictions. Amylyx’s operations are centered on research and development of small‑molecule combinations intended to target cellular stress and neurodegeneration pathways, together with the clinical development, regulatory engagement and commercialization activities required to advance its pipeline.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
2258 M
Market cap (USD)
1,832,489
Daily traded volume (Shares)
3.89 / 3.73
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
